Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
  • C07D487/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the present invention is concerned with a novel 1,2-annelated quinazoline enantiomer, the preparation thereof, pharmaceutical compositions comprising said novel compound and the use of this compound as a medicine as well as methods of treatment by administering said compound.
• Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis.
• Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells.
• Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer.
• a particular group of oncogenes is known as ras which have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts.
• the family of mammalian ras oncogenes consists of three major members (“isoforms”): H-ras, K-ras and N-ras oncogenes. These ras oncogenes code for highly related proteins generically known as p21 ras . Once attached to plasma membranes, the mutant or oncogenic forms of p21 ras will provide a signal for the transformation and uncontrolled growth of malignant tumor cells. To acquire this transforming potential, the precursor of the p21 ras oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide.
• farnesyl transferase inhibitors can be very useful as anticancer agents for tumors in which ras contributes to transformation.
• WO 97/16443, WO 97/21701, WO 98/40383 and WO 98/49157 there are described 2-quinolone derivatives which exhibit farnesyl transferase inhibiting activity.
• Other quinolone compounds having farnesyl transferase inhibiting activity are described in WO 00/12498, 00/12499 and 00/47574.
• WO 00/39082 describes a class of novel 1,2-annelated quinoline and quinazoline compounds, bearing a nitrogen- or carbon-linked imidazole, which show farnesyl protein transferase inhibiting activity.
• the present invention thus concerns ( ⁇ )-5-(3-chlorophenyl)- ⁇ -(4-chlorophenyl)- ⁇ -(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts.
• the compound of the invention is generally present in a substantially pure form, i.e. substantially free of the opposite (+) enantiomer, for example containing less than 5% w/w, preferably less then 2% w/w, and advantageously less than 1% w/w of the latter enantiomer.
• the pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compound of the invention is able to form.
• the latter compound can be converted into its pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid.
• Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e.
• butanedioic acid maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-amino-salicylic, pamoic and the like acids.
• acid addition salts also comprises the hydrates and the solvent addition forms which the compound of the invention is able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
• the ( ⁇ ) enantiomer according to the present invention may be prepared by separation of the parent enantiomeric mixture described in the above WO 00/39082.
• the separation may be effected in conventional manner for example by reaction with a suitable chiral acid such as (+)-6-aminopenicillanic acid, D or L aspartic acid, (1S,3R) or (1R,3S)-camphoric acid, (1S) or (1R)-10-camphorsulfonic acid, carbobenzyloxy-L-proline, cholic acid, dehydrocholic acid, deoxycholic acid, (2S,3S) or (2R,3R) dibenzoyltartaric acid, (2S,3S) or (2R,3R) diacetyltartaric acid, (2S,3S) or (2R,3R)-tartaric acid, (2S,3S) or (2R,3R) ditoluoyltartaric acid; 2,3:4,6-di-O
• An alternative manner of separating the desired enantiomeric form from the parent mixture involves liquid chromatography using a chiral stationary phase.
• the pure enantiomeric form may also be derived from the corresponding pure enantiomeric form of the appropriate starting materials, provided that the reaction occurs stereospecifically.
• the pure enantiomeric form may also be obtained starting from an appropriate racemic starting material provided that the reaction occurs enantiospecifically.
• the pure enantiomeric form can be prepared by reacting the parent enantiomeric mixture with one enantiomer of some chiral agents such as acids or acid chlorides to obtain diastereoisomeric mixtures, separating it, for example by selective or fractional crystallization or by using liquid chromatography, into pure diastereoisomers. The appropriate diastereoisomer can then be cleaved into the desired enantiomer.
• the parent enantiomeric mixture may be prepared in accordance with the processes described in the above WO 00/39082 or as described more specifically herein.
• the compound of the invention and its pharmaceutically acceptable acid addition salts have valuable pharmacological properties in that they have a farnesyl protein transferase (FPTase) inhibitory effect which is surprisingly potent in comparison with that of the parent enantiomeric mixture.
• FPTase farnesyl protein transferase
• the latter mixture has a IC50 FPTase inhibitory activity of 1.1 nM whereas the ( ⁇ ) enantiomer has a corresponding activity of 0.7 nM.
• This invention provides a method for inhibiting the abnormal growth of cells, including transformed cells, by administering an effective amount of the compound of the invention.
• Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g. loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated ras oncogene; (2) tumor cells in which the ras protein is activated as a result of oncogenic mutation of another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant ras activation occurs.
• tumor cells tumor cells expressing an activated ras oncogene
• tumor cells in which the ras protein is activated as a result of oncogenic mutation of another gene
• benign and malignant cells of other proliferative diseases in which aberrant ras activation occurs.
• ras oncogenes not only contribute to the growth of tumors in vivo by a direct effect on tumor cell growth but also indirectly, i.e
• This invention also provides a method for inhibiting tumor growth by administering an effective amount of the compound of the invention to a subject, e.g. a mammal (and more particularly a human) in need of such treatment.
• this invention provides a method for inhibiting the growth of tumors expressing an activated ras oncogene by the administration of an effective amount of the compound of the invention.
• tumors which may be inhibited, but are not limited to, lung cancer (e.g. adenocarcinoma and including non-small cell lung cancer), pancreatic cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g.
• colorectal carcinomas such as, for example, colon adenocarcinoma and colon adenoma
• hematopoietic tumors of lymphoid lineage e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma
• myeloid leukemias for example, acute myelogenous leukemia (AML)
• thyroid follicular cancer myelodysplastic syndrome (MDS)
• tumors of mesenchymal origin e.g. fibrosarcomas and rhabdomyosarcomas
• melanomas teratocarcinomas
• neuroblastomas gliomas
• gliomas benign tumor of the skin
• breast carcinoma e.g. advanced breast cancer
• kidney carcinoma ovary carcinoma
• bladder carcinoma e.g. advanced breast cancer
• This invention may also provide a method for inhibiting proliferative diseases, both benign and malignant, wherein ras proteins are aberrantly activated as a result of oncogenic mutation in genes. With said inhibition being accomplished by the administration of an effective amount of the compound described herein, to a subject in need of such a treatment.
• the benign proliferative disorder neuro-fibromatosis, or tumors in which ras is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited by the compounds of this invention.
• the compound according to the invention can be used for other therapeutic purposes, for example:
• Athropathies such as rheumatoid arthritis, osteoarthritis, juvenile arthritis, gout, polyarthritis, psoriatic arthritis, ankylosing spondylitis and systemic lupus erythematosus, for example as described in WO 00/01386;
• d) treating inflammatory conditions such as ulcerative colitis, Crohn's disease, allergic rhinitis, graft vs host disease, conjunctivitis, asthma, ARDS, Behcets disease, transplant rejection, uticaria, allergic dermatitis, alopecia areata, scleroderma, exanthem, eczema, dermatomyositis, acne, diabetes, systemic lupus erythematosis, Kawasaki's disease, multiple sclerosis, emphysema, cystic fibrosis and chronic bronchitis;
• inflammatory conditions such as ulcerative colitis, Crohn's disease, allergic rhinitis, graft vs host disease, conjunctivitis, asthma, ARDS, Behcets disease, transplant rejection, uticaria, allergic dermatitis, alopecia areata, scleroderma, exanthem, eczema, dermatomy
• g) treating pathologies resulting from heterotrimeric G protein membrane fixation including diseases related to following biological functions or disorders; smell, taste, light, perception, neurotransmission, neurodegeneration, endocrine and exocrine gland functioning, autocrine and paracrine regulation, blood pressure, embryogenesis, viral infections, immunological functions, diabetes, obesity;
• inhibiting viral morphogenesis for example by inhibiting the prenylation or the post-prenylation reactions of a viral protein such as the large delta antigen of hepatitis D virus; and the treatment of HIV infections;
• the present invention discloses the compound of the invention for use as a medicine as well as the use of this compound for the manufacture of a medicament for treating one or more of the above mentioned conditions.
• the compound of the invention may be advantageously employed in combination with one or more other anti-cancer agents for example selected from platinum coordination compounds for example cisplatin or carboplatin, taxane compounds for example paclitaxel or docetaxel, camptothecin compounds for example irinotecan or topotecan, anti-tumor vinca alkaloids for example vinblastine, vincristine or vinorelbine, anti-tumor nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine, nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine, anti-tumor anthracycline derivatives for example daunorubicin, doxorubicin or idarubicin; HER2 antibodies for example trastzumab; and anti-tumor podophyllotoxin derivatives for example etopo
• platinum coordination compounds for example cisp
• the subject compound may be formulated into various pharmaceutical forms for administration purposes.
• compositions of this invention an effective amount of the compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
• a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
• These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection.
• any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
• the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included.
• Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
• the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
• These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
• Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
• an effective amount would be from 0.01 mg/kg to 100 mg/kg body weight, and in particular from 0.05 mg/kg to 10 mg/kg body weight.
• a daily dose 10 to 600 mg, advantageously 50 to 500 mg and especially 100 to 400 mg of active ingredient, doses of 200 or 300 mg being particularly preferred.
• Said sub-doses may be formulated as unit dosage forms, for example, containing 10 to 500 mg, and in particular 50 mg to 300 mg of active ingredient per unit dosage form; dosage units containing 50 mg, 100 mg, 200 mg or 300 mg of active ingredient are especially preferred.
• THF tetrahydrofuran
• DIPE diisopropylether
• EtOAc ethyl acetate
• the wet powder mixture is sieved, dried and sieved again.
• 100 g microcrystalline cellulose and 15 g hydrogenated vegetable oil are added.
• the whole is mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of a compound of formula (I).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Pulmonology (AREA)
• Dermatology (AREA)
• Immunology (AREA)
• Rheumatology (AREA)
• Surgery (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pain & Pain Management (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Ophthalmology & Optometry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=8171675

Family Applications (3)

Family Applications After (2)

Country Status (34)

Cited By (6)

Families Citing this family (3)

Citations (4)

Family Cites Families (16)

• 2001
  • 2001-05-29 JO JO200183A patent/JO2361B1/en active
  • 2001-06-13 MX MXPA02012845A patent/MXPA02012845A/es active IP Right Grant
  • 2001-06-13 CA CA002410232A patent/CA2410232C/en not_active Expired - Lifetime
  • 2001-06-13 US US10/312,301 patent/US20030114471A1/en not_active Abandoned
  • 2001-06-13 UA UA20021210152A patent/UA73572C2/uk unknown
  • 2001-06-13 BR BRPI0111743-2 patent/BRPI0111743B8/pt not_active IP Right Cessation
  • 2001-06-13 PL PL358918A patent/PL209521B1/pl unknown
  • 2001-06-13 CZ CZ2003114A patent/CZ295278B6/cs not_active IP Right Cessation
  • 2001-06-13 EE EEP200200695A patent/EE04966B1/xx unknown
  • 2001-06-13 AT AT01938263T patent/ATE294804T1/de active
  • 2001-06-13 ES ES01938263T patent/ES2241830T3/es not_active Expired - Lifetime
  • 2001-06-13 AU AU6396201A patent/AU6396201A/xx active Pending
  • 2001-06-13 JP JP2002504258A patent/JP4919575B2/ja not_active Expired - Lifetime
  • 2001-06-13 IL IL15356001A patent/IL153560A0/xx unknown
  • 2001-06-13 CN CNB018113788A patent/CN1207296C/zh not_active Expired - Lifetime
  • 2001-06-13 EP EP01938263A patent/EP1296984B1/en not_active Expired - Lifetime
  • 2001-06-13 AU AU2001263962A patent/AU2001263962B2/en not_active Expired
  • 2001-06-13 KR KR1020077026608A patent/KR100846370B1/ko active IP Right Grant
  • 2001-06-13 DE DE60110592T patent/DE60110592T2/de not_active Expired - Lifetime
  • 2001-06-13 NZ NZ522481A patent/NZ522481A/en not_active IP Right Cessation
  • 2001-06-13 KR KR1020027014678A patent/KR100831940B1/ko active IP Right Grant
  • 2001-06-13 WO PCT/EP2001/006747 patent/WO2001098302A1/en active IP Right Grant
  • 2001-06-13 HU HU0300872A patent/HU229095B1/hu unknown
  • 2001-06-13 EA EA200300048A patent/EA005065B1/ru not_active IP Right Cessation
  • 2001-06-13 SK SK50-2003A patent/SK285699B6/sk not_active IP Right Cessation
  • 2001-06-14 PA PA20018519501A patent/PA8519501A1/es unknown
  • 2001-06-20 EG EG20010660A patent/EG24180A/xx active
  • 2001-06-20 MY MYPI20012896A patent/MY127734A/en unknown
  • 2001-06-21 AR ARP010102954A patent/AR030704A1/es not_active Application Discontinuation
  • 2001-09-10 SA SA01220349A patent/SA01220349B1/ar unknown
• 2002
  • 2002-10-25 IS IS6590A patent/IS2596B/is unknown
  • 2002-11-25 BG BG107310A patent/BG65894B1/bg unknown
  • 2002-12-12 HR HR20020989A patent/HRP20020989B1/xx not_active IP Right Cessation
  • 2002-12-16 NO NO20026032A patent/NO324494B1/no not_active IP Right Cessation
  • 2002-12-19 ZA ZA200210305A patent/ZA200210305B/en unknown
  • 2002-12-19 IL IL153560A patent/IL153560A/en not_active IP Right Cessation
• 2004
  • 2004-02-18 HK HK04101163A patent/HK1058363A1/xx not_active IP Right Cessation
• 2006
  • 2006-09-20 AU AU2006220405A patent/AU2006220405B2/en not_active Expired
• 2007
  • 2007-01-31 US US11/669,587 patent/US8329714B2/en active Active
  • 2007-10-29 US US11/926,741 patent/US8318753B2/en active Active

Patent Citations (5)

Also Published As

Similar Documents

Legal Events